疾病改变多发性硬化症的策略:打击残疾的新希望之光?
Carlo Maria Bellanca1,2, Egle Augello1,2, Alice Mariottini3
1Department of Biomedical and Biotechnological Sciences (BIOMETEC), Section of Pharmacology, University of Catania, 95123 Catania, Italy.
Current neuropharmacology
|January 26, 2024
概括
多发性硬化症 (MS) 治疗已经取得了显著的进步,为复发性缓解性多发性硬化症提供了新的疾病修饰疗法 (DMT).未来的研究重点是了解渐进性多发性硬化症,以开发新的,有效的治疗方法和潜在的治疗方法.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 神经科学是一个神经科学.
背景情况:
- 多发性硬化症 (MS) 是中枢神经系统 (CNS) 的慢性,自身免疫性炎症性脱髓化疾病,通常影响年轻成年人.
- 多发性硬化症的特征是不同的临床表型和多个中枢神经系统功能系统的参与.
- 虽然复发性缓解性多发性硬化症 (RRMS) 的治疗改善了结果,但渐进性形式仍然是一个治疗挑战.
结论:
- 目前的多发性硬化症管理策略改善了患者的治疗结果,特别是RRMS.
- 未来的研究工作对于开发进展性MS的有效治疗方法至关重要.
- 像神经保护和细胞疗法这样的创新方法对MS的管理和潜在的治愈充满希望.
更多相关视频
05:44Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
Published on: October 13, 2023
1.4K
09:38Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
12.3K
相关概念视频
Myasthenia Gravis: Overview and Treatment
1.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.4K
Parkinson's Disease: Overview
547
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
547
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
